As regulatory perspectives on New Approach Methodologies (NAMs) continue to evolve, the biopharma industry is increasingly focused on integrating more human relevant in vitro systems to strengthen predictivity and support early stage decision making. In this webinar, Lonza Bioscience Solutions’ R&D experts will explore how primary human cells, optimized media systems, and specialized tissue acquisition services serve as foundational components for building the next generation of complex in vitro models.
Manisha Nautiyal
Principal Scientist, R&D Cell Discovery, Lonza
Manisha is an interdisciplinary scientist with extensive experience in in vitro assay development for drug discovery and pre-clinical drug-safety studies. Her area of expertise includes the application of mammalian cell and organotypic culture models integrating high-throughput analytical approaches with novel in vitro platforms to solve drug safety problems in drug-induced liver injury and liver diseases. She currently leads several R&D innovation projects to support and expand Lonza’s primary cell, assay and media portfolio within Cell Discovery R&D at Lonza Biosciences.
Koh Meng Aw Yong
Senior Market Development Manager at Lonza
Koh Meng Aw Yong, PhD, is Senior Market Development Manager at Lonza, where he focuses on the primary cells portfolio, including PBMCs, CD34+ hematopoietic stem cells, hepatocytes, skin, airway, and other cell systems that support drug discovery and translational research. With a background spanning oncology, immunology, cell and gene therapy, and preclinical research solutions, he brings experience across product management, strategic marketing, and scientific innovation. Koh Meng is passionate about helping researchers adopt more predictive biological models and enabling better decision-making across the discovery pipeline.